Scarica l'app Stockscreener
5.52
0.18%
-0.01
Dopo l'orario di chiusura:
5.51
-0.010
-0.18%
Precedente Chiudi:
$5.53
Aprire:
$5.52
Volume 24 ore:
3.92M
Relative Volume:
5.39
Capitalizzazione di mercato:
$294.21M
Reddito:
$17.63M
Utile/perdita netta:
$-57.71M
Rapporto P/E:
-3.7297
EPS:
-1.48
Flusso di cassa netto:
$-60.45M
1 W Prestazione:
+24.04%
1M Prestazione:
-1.43%
6M Prestazione:
+70.37%
1 anno Prestazione:
+7.18%
Intervallo 1D:
$5.51
$5.53
Intervallo di 1 settimana:
$4.38
$5.62
Portata 52W:
$1.94
$6.2799
Scpharmaceuticals Inc Stock (SCPH) Company Profile
Nome
Scpharmaceuticals Inc
Settore
Industria
Telefono
617-517-0730
Indirizzo
25 BURLINGTON MALL ROAD, SUITE 203, BURLINGTON, MA
Confronta SCPH con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
SCPH
Scpharmaceuticals Inc
|
5.52 | 294.74M | 17.63M | -57.71M | -60.45M | -1.48 |
|
VRTX
Vertex Pharmaceuticals Inc
|
389.08 | 99.27B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
586.96 | 62.28B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.18 | 59.14B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
707.96 | 43.34B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
300.14 | 36.72B | 3.81B | -644.79M | -669.77M | -6.24 |
Scpharmaceuticals Inc Stock (SCPH) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2023-09-07 | Iniziato | Craig Hallum | Buy |
| 2022-12-01 | Iniziato | Cowen | Outperform |
| 2022-10-21 | Ripresa | Jefferies | Buy |
| 2022-10-11 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2022-08-02 | Iniziato | Maxim Group | Buy |
| 2021-09-09 | Iniziato | SVB Leerink | Mkt Perform |
| 2019-10-15 | Iniziato | H.C. Wainwright | Buy |
| 2019-01-30 | Downgrade | Leerink Partners | Outperform → Mkt Perform |
Mostra tutto
Scpharmaceuticals Inc Borsa (SCPH) Ultime notizie
Risk adjusted return profile for scPharmaceuticals Inc. analyzedQuarterly Market Review & High Return Trade Opportunity Guides - Newser
Published on: 2025-08-27 13:22:08 - Newser
What institutional flow reveals about scPharmaceuticals Inc.Forecast Cut & Precise Buy Zone Identification - Newser
Reversal indicators forming on scPharmaceuticals Inc. stock2025 Retail Activity & Low Drawdown Trading Techniques - Newser
Quantitative breakdown of scPharmaceuticals Inc. recent moveJuly 2025 Intraday Action & Free AI Powered Buy and Sell Recommendations - Newser
scPharmaceuticals Extends SmartDose Supply Agreement - MSN
MannKind Snaps Up scPharmaceuticals In Cardiorenal Expansion - insights.citeline.com
scPharmaceuticals downgraded to Hold from Buy at Craig-Hallum - MSN
What’s next for scPharmaceuticals Inc. stock priceEarnings Risk Report & Fast Momentum Entry Tips - Newser
scPharmaceuticals Investor Alert: Kahn Swick & Foti Investigates Proposed Sale to MannKind Corporation - AInvest
SCPHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of scPharmaceuticals Inc.SCPH - Business Wire
MannKind Announces Acquisition of scPharmaceuticals - MSN
MannKind Expands Cardiometabolic and Lung Portfolio with $360 Million Acquisition of scPharmaceuticals - Pharmaceutical Executive
Sector ETF performance correlation with scPharmaceuticals Inc.Quarterly Earnings Summary & Long-Term Capital Growth Strategies - Newser
MannKind stock price target raised to $8 by RBC on scPharmaceuticals deal - Investing.com Nigeria
Why scPharmaceuticals Inc. is moving todayEarnings Overview Report & AI Forecasted Entry and Exit Points - Newser
MannKind to acquire scPharmaceuticals - The Pharma Letter
Can scPharmaceuticals Inc. deliver consistent dividends2025 Analyst Calls & Verified Trade Idea Suggestions - sundaytimes.kr
Maxim Downgrades scPharmaceuticals to Hold From Buy - MarketScreener
MannKind Corporation to Acquire scPharmaceuticals: More Details Inside - MSN
Real time pattern detection on scPharmaceuticals Inc. stock2025 Market Trends & Fast Entry Momentum Trade Alerts - Newser
scPharmaceuticals Extends SmartDose Supply Agreement Until 2027 - AInvest
scPharmaceuticals amends supply agreement with West Pharmaceutical Services By Investing.com - Investing.com Australia
MannKind to Acquire ScPharmaceuticals in $360M Deal - USA Herald
Cooley, Latham Lead $360M ScPharmaceuticals Acquisition - Law360
MannKind To Acquire scPharmaceuticals - citybiz
MannKind, Backed By Blackstone, Expands Cardiorenal Focus With $360 Million Deal - Benzinga
Burlington biotech bought for $300M - The Business Journals
MannKind’s Strategic Acquisition of scPharmaceuticals: A Catalyst for Future Growth and Value Creation - TipRanks
Halper Sadeh LLC Investigates SCPH, VTLE, CRGY for Potential Securities Law Violations - AInvest
scPharmaceuticals Surges Amid Patent Approvals and Revenue Growth - timothysykes.com
CT maker of therapeutic inhalers agrees to acquire Mass. biopharma company in $360M deal - Hartford Business Journal
MannKind to buy scPharmaceuticals for up to $360M; Arnatar launches with $52M - Endpoints News
MannKind stock falls after announcing acquisition of scPharmaceuticals By Investing.com - Investing.com Australia
MannKind stock falls after announcing acquisition of scPharmaceuticals - Investing.com
SCPH Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of scPharmaceuticals Inc. Is Fair to Shareholders - Business Wire
MannKind to buy scPharmaceuticals to expand its cardiometabolic business - Seeking Alpha
MannKind Makes A $360 Million Move For ScPharmaceuticals - Finimize
M&A Snapshot: scPharmaceuticals rises on $360M acquisition deal by MannKind - MSN
ScPharmaceuticals Inc. Enters into an Amendment to That Certain Supply Agreement - MarketScreener
MannKind to acquire scPharmaceuticals for up to $6.35 per share - Investing.com India
MannKind to acquire scPharmaceuticals for up to $6.35 per share By Investing.com - Investing.com Canada
Shareholder Alert: The Ademi Firm Investigates Whether scPharmaceuticals Inc. Is Obtaining a Fair Price for Its Public Shareholders - Business Wire
Scpharmaceuticals Soars 13.2% on MannKind Acquisition - AInvest
M&A Snapshot: scPharmaceuticals rises on $360M acquisition deal by MannKind (MNKD:NASDAQ) - Seeking Alpha
MannKind to Acquire scPharmaceuticals for Up to $360 Million - MarketScreener
scPharmaceuticals Announces Merger with MannKind Corporation - TipRanks
MannKind to Acquire scPharmaceuticals, Accelerating Revenue - GlobeNewswire
MannKind Acquires scPharmaceuticals, Boosting Revenue Growth and Leadership in Cardiometabolic and Lung Diseases - AInvest
MannKind to Acquire scPharmaceuticals, Accelerating Revenue Growth and Emerging as a Patient-Centric Leader in Cardiometabolic and Lung Diseases - MarketScreener
$10B Market Opportunity: MannKind Acquires FUROSCIX Maker scPharmaceuticals to Dominate Cardiorenal Space - Stock Titan
Scpharmaceuticals Inc Azioni (SCPH) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.98%
8.06%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):